NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

OKUR

OnKure Therapeutics Inc

Jun 24 • 04:00PM ET

2.56

Dollar change +0.15
Percentage change 6.22	%

Healthcare • Biotechnology • USA • NASD

Peers: AXSM AKRO IDYA RNA FGEN MLTX ARCT PRLD PTGX CMRX

| Held by: VTI VXF IBB AVSC IWC IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.84	Insider Own	46.82%	Shs Outstand	12.76M	Perf Week	-1.54%
Market Cap	34.59M	Forward P/E	-	EPS next Y	-3.44	Insider Trans	-6.53%	Shs Float	7.19M	Perf Month	19.07%
Enterprise Value	-61.12M	PEG	-	EPS next Q	-1.26	Inst Own	55.26%	Short Float	7.38%	Perf Quarter	-48.39%
Income	-60.17M	P/S	-	EPS this Y	69.47%	Inst Trans	7.20%	Short Ratio	3.39	Perf Half Y	-70.27%
Sales	0.00M	P/B	0.38	EPS next Y	26.15%	ROA	-65.22%	Short Interest	0.53M	Perf YTD	-70.23%
Book/sh	6.74	P/C	0.36	EPS next 5Y	41.01%	ROE	-70.01%	52W High	20.00 -87.20%	Perf Year	-83.80%
Cash/sh	7.15	P/FCF	-	EPS past 3/5Y	43.53% 4.41%	ROIC	-66.08%	52W Low	1.70 50.59%	Perf 3Y	-87.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.45% 4.38%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	73.12%	Oper. Margin	-	ATR (14)	0.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.17	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.06	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	11.17	EPS Q/Q	52.95%	SMA20	-2.88%	Beta	0.42	Target Price	32.25
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	2.40%	Rel Volume	0.34	Prev Close	2.41
Employees	46	LT Debt/Eq	0.00	Earnings	May 06 BMO	SMA200	-70.29%	Avg Volume	156.32K	Price	2.56
IPO	Apr 09, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	13.77% -	Trades		Volume	53,465	Change	6.22%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-25	Initiated	Evercore ISI	Outperform
Dec-05-24	Initiated	Leerink Partners	Outperform	$33
Oct-10-24	Initiated	Oppenheimer	Outperform	$35
Dec-15-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-15-23	Downgrade	Jefferies	Buy → Hold
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral	$30 → $1.50
Dec-14-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-14-23	Downgrade	Robert W. Baird	Outperform → Neutral	$28 → $3
Dec-14-23	Downgrade	Piper Sandler	Overweight → Neutral	$25 → $4
Dec-14-23	Downgrade	Ladenburg Thalmann	Buy → Neutral
Dec-14-23	Downgrade	BofA Securities	Buy → Underperform	$23 → $1.45
Nov-15-23	Initiated	William Blair	Outperform	$35.55
Aug-28-23	Initiated	H.C. Wainwright	Buy	$30
Jul-03-23	Initiated	BofA Securities	Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy	$31
Jan-27-22	Initiated	Robert W. Baird	Outperform	$28
Dec-21-21	Initiated	H.C. Wainwright	Buy	$28
Nov-22-21	Initiated	Ladenburg Thalmann	Buy	$45
May-04-21	Initiated	SVB Leerink	Outperform	$25
May-04-21	Initiated	Piper Sandler	Overweight	$45

Show Previous Ratings

May-06-25 07:30AM	OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -11.16%
Mar-10-25 04:05PM	OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:00AM	OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences (GlobeNewswire) +7.45%
Dec-10-24 07:00AM	OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 (GlobeNewswire) -8.47%
Nov-25-24 05:31PM	OnKure Announces New Date for Upcoming Investor Call (GlobeNewswire)
04:05PM	Loading…
Nov-05-24 04:05PM	OnKure to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire) +7.90%
Nov-01-24 05:30PM	OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.91%
Oct-07-24 04:32AM	OnKure and Reneo Pharmaceuticals complete merger (Pharmaceutical Technology)
Oct-04-24 04:57PM	OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million (GlobeNewswire) +5.20%
Oct-02-24 08:20PM	Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure (GlobeNewswire)
Aug-13-24 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
May-16-24 10:01AM	Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing (MT Newswires)
May-13-24 08:25AM	Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise (MT Newswires) -12.15%
07:35AM	Reneo Pharmaceuticals and OnKure Announce Proposed Merger (GlobeNewswire)
May-07-24 01:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:35AM	Loading…
07:35AM	Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
Mar-28-24 12:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:35AM	Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update (GlobeNewswire)
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey)
Dec-15-23 10:19AM	Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study (Zacks) +5.97%
Dec-14-23 12:35PM	Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today? (Benzinga) -82.71%
09:05AM	Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Nov-13-23 05:04PM	Reneo Pharmaceuticals Inc (RPHM) Reports Q3 2023 Financial Results (GuruFocus.com)
07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 07:50AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 07:50AM	Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings (GlobeNewswire)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey) -5.76%
Oct-09-23 07:50AM	Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Oct-06-23 08:30AM	Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit (GlobeNewswire) +11.47%
07:35AM	Loading…
Aug-29-23 07:35AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.30%
Aug-10-23 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
07:31AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happy (Simply Wall St.)
Jul-27-23 11:19AM	Bank of America Says These 2 Stocks Could Double Your Money Heres Why They Could Rally (TipRanks) +17.59%
Jun-30-23 08:25AM	Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-26-23 08:25AM	Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices (GlobeNewswire)
Jun-15-23 12:44PM	Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023 (GlobeNewswire)
May-31-23 10:38AM	Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
08:00AM	Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-21-23 07:42PM	Insiders Pour $1 Million Each Into These 2 Strong Buy Stocks Heres Why Wall Street Thinks They Could Double (or More) (TipRanks)
May-12-23 06:00PM	MP Materials, Pitney Bowes See Activist Investor Action (Barrons.com)
May-11-23 07:45AM	Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire) +6.02%
May-03-23 11:36PM	Reneo Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-27-23 07:30AM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-23 07:30AM	Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies (GlobeNewswire)
Mar-09-23 08:00AM	Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023 (GlobeNewswire)
Mar-03-23 06:07AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last week (Simply Wall St.)
Feb-02-23 07:35AM	Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-31-23 07:35AM	Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD) (GlobeNewswire)
Dec-04-22 07:12AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-08-22 07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 08:00AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-14-22 06:02AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) biggest owners are private equity firms who got richer after stock soared 25% last week (Simply Wall St.) +8.24%
Sep-06-22 08:35AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-29-22 07:35AM	Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting (GlobeNewswire)
Aug-09-22 08:00AM	Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire) -5.26%
Aug-04-22 09:10AM	Insiders who bought in the last 12 months lose an additional US$83k as Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) drops to US$57m (Simply Wall St.) +14.89%
Aug-02-22 07:30AM	Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors (GlobeNewswire) -15.92%
Jul-26-22 09:52AM	Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development (Benzinga)
07:30AM	Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates (GlobeNewswire)
Jul-11-22 08:00AM	Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.84%
Jun-30-22 08:00AM	Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) (GlobeNewswire) +13.73%
Jun-20-22 08:33AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Invest In Growth? (Simply Wall St.)
May-10-22 04:05PM	Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results (GlobeNewswire) +9.09%
Mar-23-22 04:05PM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-22 08:30AM	Reneo Pharmaceuticals Announces Senior Leadership Promotions (GlobeNewswire)
Feb-02-22 08:00AM	Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference (GlobeNewswire) -8.93%
Jan-24-22 08:00AM	Reneo Pharmaceuticals Announces Changes to its Board of Directors (GlobeNewswire)
Jan-10-22 11:55AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.)
Dec-22-21 11:04AM	3 Strong Buy Stocks Under $10 With Triple-Digit Upside Potential (TipRanks) +15.28%
Nov-11-21 04:05PM	Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results (GlobeNewswire) +9.08% +5.23%
Nov-01-21 04:05PM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire) +6.71%
Oct-14-21 08:00AM	Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001 (GlobeNewswire)
Oct-11-21 02:35PM	Here's What Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) Shareholder Ownership Structure Looks Like (Simply Wall St.)
08:00AM	Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer (GlobeNewswire)
Sep-28-21 08:26AM	Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies (GlobeNewswire)
Sep-09-21 09:12AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.69%
Aug-11-21 05:55AM	Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-28-21 08:00AM	Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study (GlobeNewswire)
Jul-12-21 09:30AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.) +5.29%
Jul-09-21 08:00AM	Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction (GlobeNewswire)
Jul-07-21 08:00AM	Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference (GlobeNewswire)
Jun-29-21 08:00AM	Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices (GlobeNewswire)
May-20-21 06:00AM	Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results (GlobeNewswire) +6.34%
May-19-21 06:00AM	Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire) +5.62%
Apr-13-21 08:14AM	The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug (Benzinga)
Apr-09-21 12:32PM	Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today (InvestorPlace)
Apr-08-21 09:42PM	Reneo Pharmaceuticals Announces Pricing of Initial Public Offering (GlobeNewswire)

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	Former 10% Owner	May 15 '25	Sale	1.85	1,813,439	3,363,023	0	May 19 05:33 PM
ACORN BIOVENTURES, L.P.	10% Owner	May 15 '25	Buy	1.85	1,129,730	2,090,000	1,129,730	May 19 04:43 PM
ACORN BIOVENTURES, L.P.	10% Owner	May 15 '25	Buy	1.85	270,270	500,000	1,709,944	May 19 04:43 PM
Cormorant Asset Management, LP	10% Owner	May 12 '25	Sale	1.99	24,300	48,236	1,813,439	May 14 04:36 PM
Saccomano Nicholas A	President and CEO	Apr 07 '25	Sale	2.67	516	1,378	3,682	Apr 08 05:32 PM
Saccomano Nicholas A	President and CEO	Apr 04 '25	Sale	3.33	358	1,191	4,198	Apr 08 05:32 PM
Leverone Jason A.	Chief Financial Officer	Apr 07 '25	Sale	2.67	1,844	4,925	13,209	Apr 08 05:30 PM
Leverone Jason A.	Chief Financial Officer	Apr 04 '25	Sale	3.33	1,278	4,253	15,053	Apr 08 05:30 PM
Leonard Braden Michael	10% Owner	Sep 25 '24	Buy	1.50	68,746	102,872	3,457,395	Sep 26 09:33 AM
Leonard Braden Michael	10% Owner	Sep 24 '24	Buy	1.41	29,600	41,866	3,388,649	Sep 26 09:33 AM
Leonard Braden Michael	10% Owner	Sep 17 '24	Buy	1.36	55,300	75,108	3,358,243	Sep 19 11:02 AM
Leonard Braden Michael	10% Owner	Sep 18 '24	Buy	1.40	806	1,128	3,359,049	Sep 19 11:02 AM
Leonard Braden Michael	10% Owner	Sep 16 '24	Buy	1.37	172,747	236,871	3,302,943	Sep 16 04:15 PM
Leonard Braden Michael	10% Owner	Sep 13 '24	Buy	1.31	150,000	196,950	3,130,196	Sep 16 04:15 PM
Leonard Braden Michael	10% Owner	Sep 12 '24	Buy	1.40	36,176	50,523	2,980,196	Sep 16 04:15 PM
Leonard Braden Michael	10% Owner	Aug 13 '24	Buy	1.39	171,339	238,590	2,843,533	Aug 14 08:48 PM
Leonard Braden Michael	10% Owner	Aug 14 '24	Buy	1.41	100,487	142,008	2,944,020	Aug 14 08:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OKUR

OnKure Therapeutics Inc

Upgrade your FINVIZ experience